clinical trial · NCT03633396
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
Palmoplantar PustulosisImsidolimabPlacebo
brief summary
A study to evaluate the efficacy and safety, and pharmacokinetic (PK) profile of multiple doses of imsidolimab (ANB019) in adults with palmoplantar pustulosis (PPP)
started
May 20, 2019
primary completion
Apr 23, 2021
completion
Apr 23, 2021
last updated
Sep 15, 2025
official title
A Phase 2, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol